Aaron Tachibana Sells 2,931 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 2,931 shares of Personalis stock in a transaction on Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $47,540.82. Following the sale, the chief financial officer owned 195,902 shares of the company’s stock, valued at approximately $3,177,530.44. This trade represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Aaron Tachibana also recently made the following trade(s):

• On Monday, June 29th, Aaron Tachibana sold 4,982 shares of Personalis stock. The stock was sold at an average price of $14.00, for a total transaction of $69,748.00.
• On Friday, June 26th, Aaron Tachibana sold 51,251 shares of Personalis stock. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18.

Personalis Stock Up 0.7%

PSNL stock traded up $0.12 during trading on Tuesday, hitting $16.36. The company had a trading volume of 1,369,078 shares, compared to its average volume of 2,690,633. Personalis, Inc. has a 52-week low of $4.95 and a 52-week high of $18.89. The company has a 50 day simple moving average of $15.06 and a 200-day simple moving average of $10.89. The firm has a market capitalization of $1.71 billion, a P/E ratio of -15.01 and a beta of 2.31.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The company had revenue of $22.36 million during the quarter, compared to analysts’ expectations of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. Sell-side analysts forecast that Personalis, Inc. will post -1.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PSNL. Zacks Research raised Personalis from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Morgan Stanley upped their price objective on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Needham & Company LLC cut shares of Personalis from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Craig Hallum lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective on the stock. in a report on Monday, August 24th. Finally, Lake Street Capital downgraded shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective for the company. in a research note on Monday, July 20th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Personalis currently has an average rating of “Hold” and an average price target of $14.54.

Institutional Investors Weigh In On Personalis

A number of hedge funds and other institutional investors have recently bought and sold shares of PSNL. Merck & Co. Inc. purchased a new stake in shares of Personalis during the 2nd quarter valued at $188,202,236. BlackRock Inc. purchased a new stake in Personalis in the second quarter valued at about $94,905,000. Bank of America Corp DE acquired a new stake in Personalis in the second quarter worth about $24,395,000. AIGH Capital Management LLC acquired a new position in shares of Personalis during the second quarter valued at about $22,981,000. Finally, Dimensional Fund Advisors LP boosted its stake in Personalis by 8.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock worth $6,791,000 after purchasing an additional 83,074 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.